Natsume et al. summarize approaches with adoptive immunotherapies using genetically modified T cells, which have been improved by enhancing their antitumor activity, and discuss strategies to further develop these therapies.
A group of researchers from the Dana-Farber Cancer Institute (MA, USA) has conducted the largest clinical study to date of genetic abnormalities in pediatric brain tumors.
Researchers have developed novel mini ‘artificial brains’ to model glioma tumor growth: the organoids could soon be used to develop personalized treatment strategies against brain cancers.
Syndecan-4 as a biomarker to predict clinical outcome for glioblastoma multiforme treated with WT1 peptide vaccine
In this study, the authors identified SDC-4 as a biomarker to predict clinical outcome using peripheral blood mononuclear cells obtained from patients with glioblastoma, a malignant brain tumor, who were treated with WT1 peptide vaccine.
Researchers have identified a metabolic vulnerability in glioblastoma and demonstrated that it could be targeted in new therapies.
This review selectively highlights presentations from this meeting in an organizational manner that reflects clinically relevant aspects of a large and multifaceted meeting.
In this review article, the authors discuss the role of checkpoint inhibition in meningiomas and discuss the future of combined therapeutic strategies.